Biotech

Exor increases its stake in the French company bioMérieux to 8.53 per cent

Institut Mérieux will remain the majority shareholder in the French biotech company, holding 55.24 per cent of the share capital and 68.67 per cent of the voting rights.

3' min read

Translated by AI
Versione italiana

3' min read

Translated by AI
Versione italiana

Exor has increased its direct stake in bioMérieux, a company specialising in in vitro diagnostics, from 3.87 per cent to 8.53 per cent. The company, which is owned by the heirs of the Agnelli family, made the announcement, stating that it will receive the bioMérieux shares through a reduction in the stake held by the Institut Mérieux. In return, the Institut Mérieux will receive a portion of its own shares held by Exor.

Following the completion of the transaction, scheduled for December 2026, subject to the creditors’ objection period and formal approval by the shareholders of Institut Mérieux, Exor will hold 8.53 per cent of bioMérieux’s share capital and 5.35 per cent of its voting rights. Institut Mérieux will remain the majority shareholder of the French biotech company, holding 55.24 per cent of the share capital and 68.67 per cent of the voting rights. Furthermore, following the transaction, Exor will hold 5.02 per cent of the share capital of Institut Mérieux and 2.58 per cent of its voting rights.

Loading...

“Less than two years after its initial investment in the company, Exor’s decision to increase its stake in bioMérieux is a strong sign of confidence in our strategy, our growth potential and our ability to create value. We deeply appreciate this long-term perspective. The Institut Mérieux will remain our majority shareholder. The stability and support provided by the Mérieux family’s ownership have always been a strength for bioMérieux and are particularly valuable in the current changing environment,” comments Pierre Boulud, CEO of bioMérieux.

Exor’s involvement

Exor has been a shareholder in the Institut Mérieux since 2022 and a direct shareholder in bioMérieux since 2025. The board of directors of bioMérieux will propose the appointment of Benoît Ribadeau-Dumas as Exor’s representative at the next annual general meeting. Ribadeau-Dumas is already a member of the Institut Mérieux board and a non-voting observer on the bioMérieux board. The governance structure of the Institut Mérieux will remain unchanged.

‘Since 2022, our investment in the Institut Mérieux has given us first-hand insight into the Mérieux family’s entrepreneurial culture and their commitment to public health. We reaffirm our commitment as a shareholder in the Group and are delighted to further increase our stake in bioMérieux, a company we know well, which we deeply value for its leadership in the diagnostics sector and which we intend to support over the long term,” said John Elkann, Chief Executive of Exor.

The statement announcing the transaction specifies that ‘Exor and the Mérieux family do not intend to act in concert with regard to bioMérieux’.

“Over the years, we have developed a strong relationship with Exor, based on trust, close dialogue with John Elkann and the valuable contribution of Benoît Ribadeau-Dumas to our Board of Directors. Exor’s continued presence on the Institut Mérieux Board of Directors demonstrates our commitment to working in close collaboration,” commented Alexandre Mérieux, Vice-Chairman of the Institut Mérieux Board of Directors and Chairman of the bioMérieux Board, adding: “Today we welcome the increase in Exor’s direct stake in bioMérieux, which reflects our mutual confidence in the company’s strength, whilst the retention of its stake in the Institut Mérieux reaffirms its support for the Group. As the majority shareholder in bioMérieux, the Institut Mérieux will continue to support its priorities in terms of growth and innovation. The same vision guides the development of all our companies, united by a shared ambition to promote public health worldwide.”

The French biotech company

A world leader in in vitro diagnostics for 60 years, bioMérieux has a presence in 46 countries and operates in over 160 markets through an extensive network of distributors. In 2025, the group recorded revenue of 4.1 billion euros, with over 94 per cent of turnover generated outside France.

The company develops and markets diagnostic solutions – systems, reagents, software and services – to identify the causes of diseases and contamination, helping to improve patients’ health and ensure consumer safety. The products are mainly used in the diagnosis of infectious diseases, but are also used to detect microorganisms in agri-food, pharmaceutical and cosmetic products.

Copyright reserved ©
Loading...

Brand connect

Loading...

Newsletter

Notizie e approfondimenti sugli avvenimenti politici, economici e finanziari.

Iscriviti